Cytokinetics finds a new partner in Greater China for its potential blockbuster drug — it could be one of a handful of ...

In a year marked by rising protectionism and decoupling attempts in the world economic arena what has become of China allure as a favored investment ...

A key magnet is China's industrial system, which is the most comprehensive on a global scale and offers unparalleled supply ...

China's economy demonstrated remarkable resilience and adaptability in 2024, amid complex domestic and global landscapes. The ...

As Cytokinetics’ aficamten awaits approval decisions from regulators in the U.S. and China, Sanofi has picked up China rights to the cardiovascular candidate. The rights will be transferred from ...

RTW Biotech added that last Monday, Corxel said it acquired worldwide rights to an oral small molecule glucagon-like peptide-1 receptor agonist known as CX11 from Suzhou, China-based Vincentage Pharma ...

Cytokinetics (CYTK) announced that Sanofi (SNY) will acquire exclusive rights to develop and commercialize aficamten from Corxel ...

Cytokinetics, Inc. announced that Sanofi will acquire exclusive rights to aficamten from Corxel Pharmaceuticals for the treatment of hypertrophic cardiomyopathy (HCM) in Greater China. Aficamten ...

INR:0244. who is the best cricket captain in the world Daiichi Sankyo's second-generation FLT3 inhibitor Vanflyta receives unfavorabl ...

CORXEL (formerly Ji Xing) acquired the rights to develop and commercialize aficamten in Greater China (including the Chinese mainland, Hong Kong SAR and Macau SAR, and Taiwan) from Cytokinetics in ...